Ok so what we have so far is the following update 4.18PM...

Ok so what we have so far is the following update 4.18PM 28/09/2021:

-------------------------------------

Hi Tom,

Hope you are well.

Ive had discussions with a group of investors and instead of bombarding you with questions of a similar nature we have decided to compile a list of questions from all of us for you to hopefully asisst us with (we will post the answers on Hotcopper so all investors apart of forming this list get there answers satisfied).

Questions:

About Announcement

1. Why would you give notice of a conference call within 30 minutes of the conference call commencing? Why not announce something like that on Friday?

2. Why didn’t dr Baldwin or Loveridge participate in the conference? When will we get a chance to be able to ask them questions directly?

About Drug

3. If Presendin has been dropped, what protection against off-label use of generics does Invex have?
Is it only orphan drug designation?

4. Can you contrast the expected PK for Peptron's sustained Exenatide vs. Byetta vs. Daily Presendin or Exenatide vs. Bydureon vs. Daily Presendin


5. Why is Invex comfortable in proceeding straight to a P3 without repeating the P2 with Peptron's formulation?

6. What exactly has been licensed in/out and to whom (i.e., by how much have we cut potential profits globally by using Peptron's SR-formulation); for what cost (whether it be financial or otherwise); what are the limitations to each party during and post P3.

7. What has the FDA/EMA seen of PT320? Have they seen any of the pharmacokinetics or tolerability studies? Is the data package ready to go or will it need to be generated? How confident is Invex that the regulators would deem the current preclinical studies for PT320 to be acceptable?

8. Do you think that the preclinical and clinical data from Peptron about PT320 will change the FDA's mind on the recommended primary endpoint for the phase III trial for Presendin?


Probably give it to 12PM tonight, any other questions?